Key Points
- Labcorp CEO Adam Schechter sold 8,705 shares on March 3 at an average price of $279.96 for proceeds of $2,437,051.80, trimming his stake by 9.73% to 80,773 shares (worth about $22.6M).
- Quarterly results: Labcorp reported EPS of $4.07 (above the $3.95 consensus) on $3.52B revenue (slightly below estimates) and set FY2026 EPS guidance of 17.55–18.25; the stock traded down 1.7% to $271.13.
- The company declared a quarterly dividend of $0.72 (annualized $2.88, ~1.1% yield) and has a consensus analyst rating of "Moderate Buy" with an average price target of $304.82 after several recent upgrades.
Labcorp Holdings Inc. (NYSE:LH - Get Free Report) CEO Adam Schechter sold 8,705 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at $22,613,209.08. The trade was a 9.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Labcorp Stock Down 1.7%
NYSE LH traded down $4.79 during trading on Friday, hitting $271.13. 52,017 shares of the company traded hands, compared to its average volume of 738,548. Labcorp Holdings Inc. has a 12 month low of $209.38 and a 12 month high of $293.72. The business has a fifty day simple moving average of $270.68 and a 200 day simple moving average of $270.30. The company has a market capitalization of $22.34 billion, a P/E ratio of 25.92, a PEG ratio of 1.92 and a beta of 1.01. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60.
Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating analysts' consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same quarter in the prior year, the firm posted $3.45 EPS. The firm's revenue for the quarter was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, sell-side analysts predict that Labcorp Holdings Inc. will post 16.01 EPS for the current year.
Labcorp Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp's dividend payout ratio (DPR) is currently 27.53%.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on LH. Piper Sandler upped their price objective on shares of Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Morgan Stanley reissued an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Robert W. Baird upped their price target on shares of Labcorp from $313.00 to $326.00 and gave the company an "outperform" rating in a report on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a "hold" rating to a "buy" rating in a research note on Friday, January 23rd. Finally, Weiss Ratings raised Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, February 10th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Labcorp presently has an average rating of "Moderate Buy" and a consensus price target of $304.82.
View Our Latest Stock Report on Labcorp
Institutional Investors Weigh In On Labcorp
Institutional investors and hedge funds have recently bought and sold shares of the business. Caldwell Trust Co bought a new position in shares of Labcorp during the 2nd quarter worth about $25,000. Financial Gravity Companies Inc. acquired a new stake in Labcorp during the second quarter valued at approximately $26,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Labcorp in the 4th quarter valued at approximately $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp in the 4th quarter worth approximately $27,000. Finally, JPL Wealth Management LLC acquired a new position in Labcorp in the third quarter valued at about $28,000. Institutional investors own 95.94% of the company's stock.
Labcorp Company Profile
(
Get Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
